It's all about bile
James L. Boyer – 25 February 2009
Minichromosome maintenance protein‐2–positive portal tract lymphocytes distinguish acute cellular rejection from hepatitis C virus recurrence after liver transplantation
Esther Unitt, William Gelson, Susan E. Davies, Nicholas Coleman, Graeme J. M. Alexander – 25 February 2009 – Hepatitis C virus (HCV) is a leading indication for liver transplantation worldwide, but graft infection with HCV frequently leads to hepatic fibrosis. Acute cellular rejection (ACR) can be difficult to distinguish confidently from HCV, even with histology, but accurate diagnosis is critical because treatment of ACR may accelerate HCV‐related graft injury.
Endovascular treatment of supratruncal aortic hemorrhage following liver transplantation as a bridging procedure for hepatic retransplantation
Christoph Heidenhain, Undine Gerlach, Bernhard Gebauer, Johann Pratschke, Peter Neuhaus, Gero Puhl – 25 February 2009
Usage and outcomes of deceased donor liver allografts with preprocurement injury from blunt trauma
Irma Laurentia Antonia Geenen, Meindert Nico Sosef, Albert Shun, Michael Crawford, James Gallagher, Simone Strasser, Michael Stormon, Geoff McCaughan, Deborah Jean Verran – 25 February 2009 – The use of extended criteria donors is an effective way of reducing the shortage of deceased donor organs. Evidence of significant liver trauma in a deceased donor usually rules out transplantation of the liver. The aim of this study was to evaluate the use and outcomes of donor livers with preprocurement trauma.
Correction
25 February 2009
Induced pluripotent stem cells generated without viral integration
Reto Eggenschwiler, Tobias Cantz – 25 February 2009
Incidence of prolonged length of stay after orthotopic liver transplantation and its influence on outcomes
Jenny O. Smith, Mitchell L. Shiffman, Martha Behnke, R. Todd Stravitz, Velimir A. Luketic, Arun J. Sanyal, Doug M. Heuman, Robert A. Fisher, Adrian H. Cotterell, Daniel G. Maluf, Marc P. Posner, Richard K. Sterling – 25 February 2009 – Orthotopic liver transplantation (OLT) is the only effective treatment for end‐stage liver disease. Although most patients do well and are discharged promptly, some require prolonged length of stay (PLOS). The prevalence of PLOS, associated factors, and their impact on survival are not well defined.
Hemobilia and pancreatitis after liver transplant biopsy
Feng Li, Kristin L. Mekeel, Mackam Eleid, M.E. Harrison, K. Sudhakar Reddy, Adyr A. Moss, David C. Mulligan – 25 February 2009
Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: A pathological analysis
Valérie Paradis, Stéphane Zalinski, Emna Chelbi, Nathalie Guedj, Françoise Degos, Valérie Vilgrain, Pierre Bedossa, Jacques Belghiti – 24 February 2009 – Metabolic syndrome (MS) is a newly identified risk factor in chronic liver disease (CLD) and hepatocellular carcinoma (HCC). The aim of this study was to analyze the pathological characteristics of HCC and nontumoral liver in patients with MS as the only risk factor for liver disease in comparison with those that developed in the course of other CLDs in order to provide further insight into the physiopathology of HCC associated with MS.
Mesenchymal origin of hepatic stellate cells, submesothelial cells, and perivascular mesenchymal cells during mouse liver development
Kinji Asahina, Shirley Y. Tsai, Peng Li, Mamoru Ishii, Robert E. Maxson, Henry M. Sucov, Hidekazu Tsukamoto – 24 February 2009 – The knowledge concerning fetal hepatic stellate cells (HSCs) is scarce, and their cell lineage and functions are largely unknown. The current study isolated fetal liver mesenchymal cells from a mouse expressing β‐galactosidase under the control of Msx2 promoter by fluorescence‐activated cell sorting (FACS) and surveyed marker genes by microarray analysis.